Aleniglipron is investigational oral small-molecule GLP-1 receptor agonist (not a peptide; GSBR-1290). Aleniglipron is an experimental daily GLP-1 pill. Like orforglipron, it is a small molecule rather than a peptide, so it can be made like a regular tablet. We list it because it competes with peptide GLP-1 drugs.
Education only. Not medical advice. No dosing information.
Status (verified Oct 29, 2026): Investigational: Phase 3 (ACCOMPLISH program, started Jul 2026); not approved. Source: Phase 2 results published in Nature Medicine
Evidence tier: Phase 2 randomized trial; Phase 3 ongoing
Get alerts on legal status changes ->
What it is
Aleniglipron is an experimental daily GLP-1 pill. Like orforglipron, it is a small molecule rather than a peptide, so it can be made like a regular tablet. We list it because it competes with peptide GLP-1 drugs.
How it works
It activates the GLP-1 receptor from a pill, reducing appetite and improving blood sugar control.
What it's researched for
Obesity and overweight, with and without type 2 diabetes.
Where it shows up on Peptide Horizon
Regulatory and research timeline
- 2024-12: Phase 2 obesity trial starts (source)
- 2026-07: ACCOMPLISH-1 Phase 3 starts (source)
- 2026-08: Phase 2 results published in Nature Medicine (source)
Key trials and studies
- Phase 2 obesity (Nature Medicine 2026)
- ACCOMPLISH-1, Phase 3 (NCT07654361)
- Phase 3 with type 2 diabetes (NCT07654374)
FAQ
Is aleniglipron FDA approved?
No. It entered Phase 3 in July 2026.
Is aleniglipron a peptide?
No. It is a small-molecule GLP-1 drug taken as a pill.
Aleniglipron vs orforglipron?
Both are oral small-molecule GLP-1 drugs; orforglipron (Foundayo) is FDA approved, aleniglipron is still in trials.
Related peptides
- orforglipron FDA status and research
- ecnoglutide FDA status and research
- semaglutide FDA status and research
Get alerts on legal status changes
Free email alerts when the FDA, HHS or another regulator changes the status of Aleniglipron or other peptides. Get alerts ->
Sources
- https://pubmed.ncbi.nlm.nih.gov/42249138
- https://clinicaltrials.gov/study/NCT07654361
- https://clinicaltrials.gov/study/NCT07654374
Editorial review - Last reviewed Oct 29, 2026